论文部分内容阅读
目的研究血清肿瘤标志物ＣＡ２４２对胰腺癌的临床价值。方法采用免疫放射分析法（ＩＲＭＡ）对胰腺癌、良性胰胆疾病、非胰腺消化道肿瘤患者血清中ＣＡ２４２含量进行测定。结果血清ＣＡ２４２阳性率，胰腺癌为７３．１％，良性胰胆疾病为９５％，非胰腺消化道肿瘤为２５０％。ＣＡ２４２的血清值与胰腺肿瘤负荷呈正相关。胰腺癌可切除组ＣＡ２４２的血清值明显低于不可切除组。胰腺癌切除术后ＣＡ２４２的血清值明显下降，无法切除胰腺癌术后ＣＡ２４２血清值无明显变化。结论ＣＡ２４２可作为诊断胰腺癌的辅助指标，也可为胰腺癌切除的有效性提供参考信息
Objective To study the clinical value of serum tumor marker CA242 in pancreatic cancer. Methods The serum CA242 level in patients with pancreatic cancer, benign pancreatic and biliary diseases, and non-pancreatic digestive tract tumors was determined by immunoradiometric assay (IRMA). Results The positive rate of serum CA242 was 73.1% for pancreatic cancer, 9.5% for benign pancreatic and biliary diseases, and 25.0% for non-pancreatic digestive tract tumors. The serum level of CA242 was positively correlated with pancreatic tumor burden. The serum level of CA242 in the resectable pancreatic cancer group was significantly lower than that in the unresectable group. The serum level of CA242 after pancreatic cancer resection was significantly decreased, and there was no significant change in the serum CA242 serum level after unresectable pancreatic cancer. Conclusion CA242 can be used as an auxiliary index to diagnose pancreatic cancer, and it can also provide reference for the effectiveness of pancreatic cancer resection.